CT与PET/CT影像组学预测非小细胞肺癌淋巴结转移的诊断准确性
该系统评价与Meta分析纳入22项研究共42个队列,评估CT与PET/CT影像组学预测非小细胞肺癌淋巴结转移的准确性。CT影像组学汇总敏感度0.84、特异度0.82、AUC 0.90;PET/CT影像组学敏感度0.82、特异度0.86、AUC 0.90。作者认为模型具有预测准确性,但需更大规模多中心研究进一步验证。
要点
- CT影像组学预测非小细胞肺癌淋巴结转移的汇总敏感度0.84、特异度0.82、AUC 0.90。
- PET/CT影像组学汇总敏感度0.82、特异度0.86、AUC 0.90。
- CT研究未检出发表偏倚(P=0.54),PET/CT研究存在轻度发表偏倚(P=0.03)。
核心结论
- 影像组学模型在预测肺癌淋巴结转移方面显示出准确性,但尚需更大规模的多中心研究进一步验证。
- 使用CT和PET/CT的影像组学模型可能改善肺癌淋巴结转移的预测,有助于个体化治疗策略。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA和AMSTAR指南,检索PubMed、Web of Science和Embase数据库2012年3月至2023年12月的文献。
- 纳入使用CT和PET/CT影像的影像组学研究,最终分析纳入22项研究的42个队列。
- 采用QUADAS-2和RQS工具评价研究质量,TRIPOD清单评估模型透明度。
- 合并敏感度、特异度和AUC值以评估诊断性能,并进行亚组分析和敏感性分析探讨异质性,用Fagan图评估临床适用性。
- 研究已在PROSPERO注册,注册号CRD42023494701,注册日期2023年12月18日。
诊断标准与关键数值
- CT影像组学:敏感度0.84(95%CI 0.79-0.88,p<0.01),特异度0.82(95%CI 0.75-0.87,p<0.01),AUC 0.90(95%CI 0.87-0.92)。
- PET/CT影像组学:敏感度0.82(95%CI 0.76-0.86,p<0.01),特异度0.86(95%CI 0.81-0.90,p<0.01),AUC 0.90(95%CI 0.87-0.93)。
- CT影像组学未检出发表偏倚(p=0.54>0.05);PET/CT影像组学存在轻度发表偏倚(p=0.03<0.05)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 亚组分析未能阐明异质性来源,提示可能受淋巴结位置和亚组样本量小等因素影响。
- PET/CT影像组学分析存在轻度发表偏倚(p=0.03<0.05)。
- 作者结论指出需更大规模的多中心研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study evaluates the accuracy of radiomics in predicting lymph node metastasis in non-small cell lung cancer, which is crucial for patient management and prognosis.
METHODS: Adhering to PRISMA and AMSTAR guidelines, we systematically reviewed literature from March 2012 to December 2023 using databases including PubMed, Web of Science, and Embase. Radiomics studies utilizing computed tomography (CT) and positron emission tomography (PET)/CT imaging were included. The quality of studies was appraised with QUADAS-2 and RQS tools, and the TRIPOD checklist assessed model transparency. Sensitivity, specificity, and AUC values were synthesized to determine diagnostic performance, with subgroup and sensitivity analyses probing heterogeneity and a Fagan plot evaluating clinical applicability.
RESULTS: Our analysis incorporated 42 cohorts from 22 studies. CT-based radiomics demonstrated a sensitivity of 0.84 (95% CI: 0.79-0.88, p < 0.01) and specificity of 0.82 (95% CI: 0.75-0.87, p < 0.01), with an AUC of 0.90 (95% CI: 0.87-0.92), indicating no publication bias (p-value = 0.54 > 0.05). PET/CT radiomics showed a sensitivity of 0.82 (95% CI: 0.76-0.86, p < 0.01) and specificity of 0.86 (95% CI: 0.81-0.90, p < 0.01), with an AUC of 0.90 (95% CI: 0.87-0.93), with a slight publication bias (p-value = 0.03 < 0.05). Despite high clinical utility, subgroup analysis did not clarify heterogeneity sources, suggesting influences from possible factors like lymph node location and small subgroup sizes.
CONCLUSIONS: Radiomics models show accuracy in predicting lung cancer lymph node metastasis, yet further validation with larger, multi-center studies is necessary.
CLINICAL RELEVANCE STATEMENT: Radiomics models using CT and PET/CT imaging may improve the prediction of lung cancer lymph node metastasis, aiding personalized treatment strategies.
RESEARCH REGISTRATION UNIQUE IDENTIFYING NUMBER (UIN): International Prospective Register of Systematic Reviews (PROSPERO), CRD42023494701. This study has been registered on the PROSPERO platform with a registration date of 18 December 2023. https://www.crd.york.ac.uk/prospero/ KEY POINTS: The study explores radiomics for lung cancer lymph node metastasis detection, impacting surgery and prognosis. Radiomics improves the accuracy of lymph node metastasis prediction in lung cancer. Radiomics can aid in the prediction of lymph node metastasis in lung cancer and personalized treatment.
引用
- Li Y, Deng J, Ma X, et al. Diagnostic accuracy of CT and PET/CT radiomics in predicting lymph node metastasis in non-small cell lung cancer. Eur Radiol. 2024. PMID: 39223336. doi:10.1007/s00330-024-11036-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。